PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.78%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
74.78%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
64.85%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
64.71%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
64.71%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-60.52%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-60.52%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
51.61%
OCF/share CAGR of 51.61% while AVXL is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
51.61%
OCF/share CAGR of 51.61% while AVXL is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
51.61%
3Y OCF/share CAGR of 51.61% while AVXL is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
66.06%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
66.06%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
66.06%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
Negative asset growth while AVXL invests at 20.20%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-5.28%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
11.50%
Debt shrinking faster vs. AVXL's 92.01%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
-73.61%
We cut SG&A while AVXL invests at 149.01%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.